TOKYO, Japan -- January 29, 2018 -- Terumo Corporation (TSE: 4543) announced today that it integrated the Silicon Valley Lab research and development facilities, located in northern California in the United States, with, Kalila Medical, Inc., a subsidiary of Terumo Corporation, on January 10, 2018. Terumo moved both facilities to a new site, now called the Terumo Bay Area Innovation Lab. Over the next five years, plans call for the new lab to employ up to 50 people, about twice the current number.
Terumo established the Silicon Valley Lab in 2015. There, an R&D team transferred from Japan, along with some local personnel, primarily conducted early-stage research and development of products for the U.S. market. Kalila was a subsidiary that joined Terumo from Abbott Laboratories, a U.S-based company, in January 2017. Kalila developed products for use with ablation treatment systems. By integrating the two R&D facilities, Terumo aims to accelerate the launch of corporate R&D projects while expanding its lineup of steerable sheaths for use with ablation systems.
In addition to the new Terumo Bay Area Innovation Lab, Terumo has been taking advantage of the concentration of medical technologies in Silicon Valley to develop innovative medical devices. Terumo invested in a venture fund in 2013. Then, in 2014, it established a subsidiary, Terumo Medical Innovation Inc., to engage in development projects onsite at hospitals. By taking these steps, Terumo has positioned itself to explore new technologies and ideas while conducting early-stage product development.
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.